Supernus Pharmaceuticals, Inc.
SUPNSupernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing central nervous system (CNS) therapies. Founded in 2005 and headquartered in Durham, North Carolina, the company specializes in treatments for conditions such as epilepsy, migraine, and psychiatric disorders. Supernus is known for its focus on formulations that improve patient adherence and quality of life.
Company News
Aristotle Capital Boston reduced its holdings in Pharmaceuticals by 503,122 shares in Q3, decreasing its position value by approximately $10.9 million. Despite a 31% stock price increase over the past year, the company remains below its 2018 highs.
Supernus Pharmaceuticals announced the expiration of the HSR Act waiting period for its proposed acquisition of Sage Therapeutics, with the tender offer continuing and set to expire on July 30, 2025.
Supernus Pharmaceuticals, a biopharmaceutical company focused on central nervous system diseases, will host a conference call on February 25, 2025, to discuss its fourth quarter and full-year 2024 financial results.
Supernus Pharmaceuticals, a biopharmaceutical company focused on central nervous system diseases, announced that its President and CEO will participate in a fireside chat at the Piper Sandler Healthcare Conference.
The global ADHD treatment market is expected to grow at a CAGR of 3.1% from 2024 to 2034, reaching $15.4 billion by 2034. The growth is driven by increased awareness of ADHD and ongoing research and development efforts.
